# Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies

> **NCT07131449** · — · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 200 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **OTHER:** This is observational studies, participants are not assigned an intervention as part of the study.

## Key facts

- **NCT ID:** NCT07131449
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131449, "Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07131449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*